Articles citing this paper
Use of priority and provisional approval pathways by the Australian Therapeutic Goods Administration in approving new medicines: a cross-sectional study
Joel Lexchin
A B *
+ Author Affiliations
- Author Affiliations
A School of Health Policy and Management, York University, 4700 Keele Street, Toronto, ON M3J 1P3, Canada.
B Faculty of Medicine, University of Toronto, Toronto, ON M5S 1AA, Canada.
* Correspondence to: jlexchin@yorku.ca
Australian Health Review 46(3) 309-315 https://doi.org/10.1071/AH22008
Submitted: 19 January 2022 Accepted: 23 February 2022 Published: 5 May 2022
3 articles found in Crossref database.
The increasing costs of medicines and their implications for patients, physicians and the health system
Ghinea Narcyz
Internal Medicine Journal. 2024 54(4). p.545
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway
Shahzad Mahnum,
Naci Huseyin,
Esselen Katharine M.,
Dottino Joseph A., Wagner Anita K.
Journal of Pharmaceutical Policy and Practice. 2024 17(1).
A Survey of Industry Perceptions of Facilitated Regulatory Pathways in Drug Development in Australia
Yoffe Alina,
Liu Johnson,
Smith Greg, Chisholm Orin
Pharmaceutical Medicine. 2023 37(5). p.385
